What development phase is Prodif in?

Prodif is FDA-approved (marketed).

What is the generic name of Prodif?

FOSFLUCONAZOLE is the generic (nonproprietary) name of Prodif.

Last reviewed 2026-04-20 · How we verify

Prodif (FOSFLUCONAZOLE)

FDA-approved active Small molecule Quality 15/100

Prodif (FOSFLUCONAZOLE) is a small molecule drug in the fosfluconazole class, but its target and approved indications are unknown. Its half-life is approximately 2.1 hours. The commercial status of Prodif is unclear, and it is not known if it is patented or available as a generic. Further information on its bioavailability, generic manufacturers, and FDA approval status is also unavailable. As a result, key safety considerations and approved indications cannot be determined.

At a glance

Generic name	FOSFLUCONAZOLE
Drug class	fosfluconazole
Target	Lanosterol 14-alpha demethylase
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prodif CI brief — competitive landscape report
Prodif updates RSS · CI watch RSS